Uchenne Muscular Dystrophy - Pipeline Review, H1 2017
ReportsWeb.com published “Uchenne Muscular Dystrophy Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
(EMAILWIRE.COM, October 05, 2017 ) ReportsWeb.com published “Uchenne Muscular Dystrophy Market” from its database. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Original Content:
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
For more information about this report: http://www.reportsweb.com/duchenne-muscular-dystrophy-pipeline-review-h1-2017
Publisher's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders) .
- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001709484/sample
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
Companies Mentioned:
Acceleron Pharma Inc
Akashi Therapeutics Inc
Asklepios BioPharmaceutical Inc
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Company
Capricor Therapeutics Inc
Cardero Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Daiichi Sankyo Company Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Ltd
FibroGen Inc
Galapagos NV
Genethon SA
GTx Inc
GW Pharmaceuticals Plc
Idera Pharmaceuticals Inc
Italfarmaco SpA
La Jolla Pharmaceutical Company
Lexicon Pharmaceuticals Inc
Marina Biotech Inc
Merck KGaA
Inquire for Report at http://www.reportsweb.com/buy&RW0001709484/buy/2000
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Original Content:
Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2017, provides an overview of the Duchenne Muscular Dystrophy (Genetic Disorders) pipeline landscape.
Duchenne muscular dystrophy is a condition which causes muscle weakness. DMD is an X-linked disorder. The gene for DMD is present on the X chromosome. It codes for a protein named dystrophin. Dystrophin is essential for providing structural support inside muscle cells. Symptoms usually appear before age 6 and may appear as early as infancy. They include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
For more information about this report: http://www.reportsweb.com/duchenne-muscular-dystrophy-pipeline-review-h1-2017
Publisher's Pharmaceutical and Healthcare latest pipeline guide Duchenne Muscular Dystrophy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Duchenne Muscular Dystrophy (Genetic Disorders) .
- The pipeline guide reviews pipeline therapeutics for Duchenne Muscular Dystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Duchenne Muscular Dystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001709484/sample
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Duchenne Muscular Dystrophy (Genetic Disorders) .
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Duchenne Muscular Dystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
Companies Mentioned:
Acceleron Pharma Inc
Akashi Therapeutics Inc
Asklepios BioPharmaceutical Inc
BioMarin Pharmaceutical Inc
Bristol-Myers Squibb Company
Capricor Therapeutics Inc
Cardero Therapeutics Inc
Catabasis Pharmaceuticals Inc
CRISPR Therapeutics
Daiichi Sankyo Company Ltd
Debiopharm International SA
Editas Medicine Inc
Eloxx Pharmaceuticals Ltd
FibroGen Inc
Galapagos NV
Genethon SA
GTx Inc
GW Pharmaceuticals Plc
Idera Pharmaceuticals Inc
Italfarmaco SpA
La Jolla Pharmaceutical Company
Lexicon Pharmaceuticals Inc
Marina Biotech Inc
Merck KGaA
Inquire for Report at http://www.reportsweb.com/buy&RW0001709484/buy/2000
Contact Us:
Call: +1-646-491-9876
Email: sales@reportsweb.com
About ReportsWeb:
ReportsWeb.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.
Contact Information:
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
ReportsWeb.com
Rajat Sahni
Tel: +1-646-491-9876
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results